Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.56 down -4.88% from its previous closing price of $1.64. In other words, the price has decreased by -$4.88 from its previous closing price. On the day, 0.75 million shares were traded.
Ratios:
For a deeper understanding of Outlook Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.32.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Haddadin Yezan Munther bought 1,882 shares of OTLK for $22,242 on Mar 28 ’24. The Director now owns 5,049 shares after completing the transaction at $11.82 per share. On Mar 07 ’24, another insider, Evanson Jeff, who serves as the CHIEF COMMERCIAL OFFICER of the company, bought 62,484 shares for $0.42 each. As a result, the insider paid 26,243 and bolstered with 808,459 shares of the company.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $12.85, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is -15.81%, while the 200-Day Moving Average is calculated to be -71.23%.
Shares Statistics:
A total of 24.91M shares are outstanding, with a floating share count of 23.59M. Insiders hold about 26.33% of the company’s shares, while institutions hold 14.44% stake in the company.
